T. Rowe Price Associates
PRME icon

T. Rowe Price Associates’s Prime Medicine PRME Stock Holding History

T. Rowe Price Associates’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$599K Buy
162,325
+28,570
+21% +$94.9K ﹤0.01% 2542
2026
Q1 		$466K Buy
133,755
+29,202
+28% +$111K ﹤0.01% 2495
2025
Q4 		$363K Buy
104,553
+30,051
+40% +$134K ﹤0.01% 2550
2025
Q3 		$413K Buy
74,502
+9,182
+14% +$37.3K ﹤0.01% 2446
2025
Q2 		$162K Sell
65,320
-1,501,872
-96% -$2.32M ﹤0.01% 2781
2025
Q1 		$3.12M Sell
1,567,192
-17,284
-1% -$44.1K ﹤0.01% 1410
2024
Q4 		$4.63M Buy
1,584,476
+38,515
+2% +$135K ﹤0.01% 1309
2024
Q3 		$5.98M Hold
1,545,961
– – ﹤0.01% 1244
2024
Q2 		$7.95M Sell
1,545,961
-976,629
-39% -$5.92M ﹤0.01% 1142
2024
Q1 		$17.7M Buy
2,522,590
+301,431
+14% +$2.29M ﹤0.01% 1004
2023
Q4 		$19.7M Buy
2,221,159
+47,788
+2% +$368K ﹤0.01% 961
2023
Q3 		$20.7M Sell
2,173,371
-160,460
-7% -$2.08M ﹤0.01% 913
2023
Q2 		$34.2M Buy
2,333,831
+1,430,090
+158% +$20M ﹤0.01% 814
2023
Q1 		$11.1M Sell
903,741
-1,474,841
-62% -$24M ﹤0.01% 1039
2022
Q4 		$44.2M Buy
+2,378,582
New +$43M 0.01% 696

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

T. Rowe Price Associates's PRME Position: Q2 2026 in Review

T. Rowe Price Associates increased its Prime Medicine (PRME) stake by 21% in Q2 2026, buying an estimated $94.9K and bringing the position to 162,325 shares worth $599K. The position accounts for ﹤0.01% of the portfolio, ranked #2542.

T. Rowe Price Associates first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $44.2M in Q4 2022. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • T. Rowe Price Associates held 162,325 shares of Prime Medicine worth $599K as of Q2 2026.
  • T. Rowe Price Associates bought 28,570 Prime Medicine shares in Q2 2026, an estimated $94.9K.
  • Prime Medicine made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2542 holding.
  • T. Rowe Price Associates first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • T. Rowe Price Associates's Prime Medicine position peaked at $44.2M in Q4 2022.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.